Liquidia (NASDAQ:LQDA) Director Katherine Rielly-Gauvin Sells 36,789 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Katherine Rielly-Gauvin sold 36,789 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $74.99, for a total value of $2,758,807.11. Following the completion of the transaction, the director directly owned 44,637 shares in the company, valued at approximately $3,347,328.63. This trade represents a 45.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Katherine Rielly-Gauvin also recently made the following trade(s):

• On Thursday, August 20th, Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock. The stock was sold at an average price of $72.23, for a total value of $1,328,526.39.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $68.62 on Friday. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of 50.09 and a beta of 0.58. The firm has a 50 day moving average of $79.29 and a 200 day moving average of $56.21. Liquidia Corporation has a 52 week low of $21.15 and a 52 week high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the prior year, the company posted ($0.49) EPS. The business’s revenue for the quarter was up 1842.1% on a year-over-year basis. On average, sell-side analysts predict that Liquidia Corporation will post 2.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia during the fourth quarter worth about $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at $25,000. Covestor Ltd increased its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the last quarter. Finally, Globeflex Capital L P purchased a new position in shares of Liquidia during the 2nd quarter worth approximately $175,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Oppenheimer set a $75.00 price objective on shares of Liquidia in a report on Friday, June 5th. Needham & Company LLC lifted their price target on Liquidia from $70.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Piper Sandler set a $129.00 price target on Liquidia in a research note on Friday, July 24th. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Hold” and an average price target of $98.08.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).